GlaxoSmithKline board to review half-year financials November 6

GlaxoSmithKline Pharmaceuticals Limited announced that its board of directors will convene on Thursday, November 6, 2025. The primary agenda for this meeting is to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2025.

The announcement, dated October 27, 2025, was made to both BSE Limited and The National Stock Exchange of India Limited, in compliance with regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR). The disclosure was signed by Ajay Nadkarni, vice president – administration, real estate & company secretary, on behalf of GlaxoSmithKline Pharmaceuticals Limited.